British National Formulary September 2025 Update

This update contains 8 significant changes, 1 dose change, 3 new monographs and 1 new preparation.

Significant Changes:

• Influenza vaccine: updated guidance for immunisation.
• Influenza vaccine (inactivated): update to ovalbumin content.
• Influenza vaccine (live): update to cautions.
• Linzagolix: new indication and dose for endometriosis.
• Respiratory syncytial virus (RSV) vaccine (Abrysvo® and Arexvy®): be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults [MHRA/CHM advice].
• Sodium valproate: update to important safety information.
• Valproate (Belvo®, Convulex®, Depakote®, Dyzantil®, Epilim®, Epilim Chrono® or Chronosphere®, Episenta®, Epival®, and Syonell®): updated safety and educational materials to support patient discussion on reproductive risks [MHRA/CHM advice] (advice in sodium valproate, valproic acid; see example in sodium valproate).
• Valproic acid: update to important safety information.

 

Dose Changes:

• Ublituximab [update to dosing for multiple sclerosis].

 

New Monographs:

• IXCHIQ® [chikungunya vaccine (live)].
• Livdelzi® [seladelpar].
• Winrevair® [sotatercept].

 

New Preparations: Tysabri® solution for injection in pre-filled syringe [natalizumab].